Sam is a professional trader and the lead stock market news writer at AskTraders. After starting his career in the forex market, Sam now focuses on gold and stocks with a preference for fundamental and macroeconomic analysis.
Shares of Marker Therapeutics (NASDAQ: MRKR) are surging premarket on Friday after the company revealed in regulatory filings that several insiders at the company purchased shares.
CEO Peter Hoang bought $250k worth of shares while Chief Development Officer Juan Vera purchased $1 million worth of stock.
Board members John Robert Wilson and Steven Elms jointly purchased $5 million worth of stock in total.
On Thursday evening, the company was also given an overweight rating by Cantor Fitzgerald, with a price target of $6 per share, representing a 233.33% increase on Thursday’s closing price of $1.81.
Premarket, Marker Therapeutics share price is up 24.44% at $2.24.
Should you invest in Marker Therapeutics shares? One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now…
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .